Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06565650 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.
A Phase 4 study of Dry Eye, sponsored by Bausch & Lomb Incorporated.
- Active
- Registry status
- Phase 4
- Development phase
- 216
- Enrollment target
- 12
- Study locations
NCT06565650 is a Phase 4 study of Dry Eye that is active but no longer recruiting, run by Bausch & Lomb Incorporated. The registered enrollment target is 216 participants, above the 90-participant average among 41 other Dry Eye trials with a reported enrollment target (140% higher). The trial reports 12 study locations across 7 states.
The verdict
NCT06565650, a Phase 4 study of Dry Eye, is active but no longer recruiting, sponsored by Bausch & Lomb Incorporated.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 216 participants
- Enrollment target
- 12
- Study locations
Study Summary
A Randomized, Multicenter, Double-Masked, Saline-Controlled Trial to Evaluate Corneal Endothelial Cell Density in Subjects With Dry Eye Disease Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months
Conditions Studied
Interventions
- DRUG Saline
- DRUG Miebo
Study Locations (12)
California
- Site 101 - Glendale
- Site 112 - Murrieta
- Site 102 - Newport Beach
- Site 109 - Rancho Cordova
- Site 106 - Torrance
Missouri
- Site 110 - Kansas City
- Site 104 - St Louis
Florida
- Site 113 - Delray Beach
Georgia
- Site 107 - Morrow
Indiana
- Site 105 - Carmel
North Carolina
- Site 108 - Asheville
Tennessee
- Site 103 - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 216 participants |
| Start Date | 2024-07-31 |
| Est. Completion | 2025-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06565650
The ClinicalTrials.gov registry entry for NCT06565650 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 216 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 90-participant average among 41 other Dry Eye trials with a reported enrollment target (140% higher). The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dry Eye appearing as the primary indexed condition, and to 2 interventions - of which Saline is the first listed.
NCT06565650 reports 12 study locations spanning 7 distinct geographic areas - top geographies include California, Missouri, Florida.
Frequently Asked Questions
What is clinical trial NCT06565650 about?
NCT06565650 is a clinical study titled "A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.". A Randomized, Multicenter, Double-Masked, Saline-Controlled Trial to Evaluate Corneal Endothelial Cell Density in Subjects With Dry Eye Disease Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months
What is the current status of trial NCT06565650?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 216 participants. The study started on 2024-07-31. Estimated completion is 2025-11.
What conditions does trial NCT06565650 study?
This clinical trial studies the following conditions: Dry Eye.
What interventions are being tested in trial NCT06565650?
The interventions under investigation include: Saline (DRUG), Miebo (DRUG).
Who is sponsoring clinical trial NCT06565650?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06565650 being conducted?
This trial has 12 study locations across California, Florida, Georgia, Indiana, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy of Kera Sol Tears on Signs and Symptoms of Surgical Temporary Ocular Discomfort Syndrome (STODS) in Subjects Following LASIK
RECRUITING · Phase 4
-
Quality of Life in Presbyopic Patients Who Are Treated With Qlosi
RECRUITING · Phase 4
-
Impact of TRYPTYR on a Patient's Quality of Life and Ability to Perform Work
RECRUITING · Phase 4
-
Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease
RECRUITING · Phase 4
-
Performance of Systane PRO Versus Refresh Optive Mega-3
RECRUITING · Phase 4
-
DOMPE -MT Neurotrophic Keratitis
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.